Results 51 to 60 of about 27,519 (289)

Trends of LSD1 Inhibitors in Viral Infections [PDF]

Future Medicinal Chemistry, 2018
.
Zwergel, Clemens, Stazi, Giulia, Mai, Antonello, Valente, Sergio   +3 more
openaire   +3 more sources

Community-aware network sparsification [PDF]

, 2017
Network sparsification aims to reduce the number of edges of a network while maintaining its structural properties; such properties include shortest paths, cuts, spectral measures, or network modularity. Sparsification has multiple applications, such as,
Gionis, Aristides, Rozenshtein, Polina, Tatti, Nikolaj, Terzi, Evimaria   +3 more
core   +2 more sources

The dual role of LESION SIMULATING DISEASE 1 as a condition-dependent scaffold protein and transcription regulator [PDF]

, 2017
Since its discovery over two decades ago as an important cell death regulator in Arabidopsis thaliana, the role of LESION SIMULATING DISEASE 1 (LSD1) has been studied intensively within both biotic and abiotic stress responses as well as with respect to ...
Balazadeh, Salma, Czarnocka, Weronika, Karpiński, Stanislaw, Mueller-Roeber, Bernd, Rusaczonek, Anna, Shahnejat-Bushehri, Sara, Szechynska-Hebda, Magdalena, Van Breusegem, Frank, Van Der Kelen, Katrien, Willems, Patrick   +9 more
core   +2 more sources

LSD1: Expanding Functions in Stem Cells and Differentiation [PDF]

Cells, 2021
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC) provide a powerful model system to uncover fundamental mechanisms that control cellular identity during mammalian development. Histone methylation governs gene expression programs that play a key role in the regulation of the balance between self-renewal and differentiation of ESCs ...
Carlos Martinez-Gamero, Sandhya Malla, Francesca Aguilo   +2 more
openaire   +4 more sources

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models [PDF]

, 2018
Background: Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such as ...
A. Ganesan, AA Shafi, Annette L. Hayden, B Laurent, C Cai, C Cai, C Parker, CJ Ryan, DE Rathkopf, E Hornberg, E Metzger, E Metzger, ES Antonarakis, ES Antonarakis, F Claessens, F Cottard, FA Ran, G Attard, G Packham, Graham Packham, H Benelkebir, Hanae Benelkebir, HI Scher, I Graca, J Ellinger, JS Bono de, JS Bono de, KJ Livak, Leon R. Douglas, M Kaarbo, M Nakazawa, M Wang, M Wissmann, M. Teresa Borrello, MR Smith, P Kahl, Patrick J. Duriez, PJ Vlachostergios, PW Kantoff, Rosemary A. Strivens, S Niraula, Sarah Bailey, Sergio Regufe da Mota, Simon J. Crabb, SJ Crabb, TM Beer, UK Laemmli, Y Shi, YJ Shi   +48 more
core   +2 more sources

Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC

Cell Death and Disease, 2023
Lysine-specific demethylase 1 (LSD1) has been identified as an important epigenetic target, and recent advances in lung cancer therapy have highlighted the importance of targeting ferroptosis.
Linna Du, Han Yang, Yufei Ren, Yanli Ding, Yichao Xu, Xiaolin Zi, Hongmin Liu, Pengxing He   +7 more
semanticscholar   +1 more source

LSD1 Histone Demethylase Assays and Inhibition [PDF]

, 2016
The lysine-specific demethylase (LSD1) is a flavin-dependent amine oxidase that selectively removes one or two methyl groups from histone H3 at the Lys4 position. Along with histone deacetylases 1 and 2, LSD1 is involved in epigenetically silencing gene expression. LSD1 has been implicated as a potential therapeutic target in cancer and other diseases.
D, Hayward, P A, Cole
openaire   +2 more sources

Polymyxins and quinazolines are LSD1/KDM1A inhibitors with unusual structural features [PDF]

, 2016
Because of its involvement in the progression of several malignant tumors, the histone lysine-specific demethylase 1 (LSD1) has become a prominent drug target in modern medicinal chemistry research.
Ciossani, Giuseppe, Forgione, Mariantonietta, Forneris, Federico, Lucidi, Alessia, Mai, Antonello, Marrocco, Biagina, Mattevi, Andrea, Mehdipour, Parinaz, Pilotto, Simona, Rotili, Dante, Speranzini, Valentina, Velankar, Sameer   +11 more
core   +2 more sources

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51

Nature Communications, 2023
Poly (ADP-ribose) polymerase inhibitors (PARPi) are selectively active in ovarian cancer (OC) with homologous recombination (HR) deficiency (HRD) caused by mutations in BRCA1/2 and other DNA repair pathway members.
Lei Tao, Yuee Zhou, Xiangyu Pan, Yuan Luo, Jia-Hui Qiu, Xia Zhou, Zhiqian Chen, Yan Li, Lian Xu, Yangli Zhou, Z. Zuo, Chunqi Liu, Liang Wang, Xiaocong Liu, Xinyu Tian, Na Su, Zhengnan Yang, Yu Zhang, Kun Gou, Na Sang, Huan Liu, Jiao Zou, Yuzhou Xiao, Xincheng Zhong, Jing Xu, Xinyu Yang, Kai Xiao, Yanyang Liu, Shengyong Yang, Yong Peng, Junhong Han, Xiaobo Cen, Yinglan Zhao   +32 more
semanticscholar   +1 more source

SYNTHESIS, LSD1 INHIBITORY ACTIVITY, AND LSD1 BINDING MODEL OF OPTICALLY PURE LYSINE-PCPA CONJUGATES

Computational and Structural Biotechnology Journal, 2014
Compounds that inhibit the catalytic function of lysine-specific demethylase 1 (LSD1) are interesting as therapeutic agents. Recently, we identified three lysine-phenylcyclopropylamine conjugates, NCD18, NCD25, and NCD41, which are potent LSD1 inactivators.
Yukihiro Itoh, Daisuke Ogasawara, Yosuke Ota, Tamio Mizukami, Takayoshi Suzuki   +4 more
openaire   +3 more sources